Stealth Bio Gears Up for IPO
Clinical-stage biotechnology company Stealth Biotherapeutics has filed with the SEC regarding its initial public offering.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Stealth Biotherapeutics has filed an F-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were mentioned in the filing, although the offering is valued up to $86.25 million. The company intends to list its American depositary shares on the Nasdaq under the symbol MITO.
The underwriters for the offering are Jefferies, Evercore ISI, BMO Capital Markets and Nomura Securities.
This is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Dysfunctional mitochondria characterize a number of rare genetic diseases, collectively known as primary mitochondrial diseases, and they are also involved in many common age-related diseases. Management believes its lead product candidate, elamipretide, has the potential to treat both rare genetic and common age-related mitochondrial diseases.
The firm’s mission is to be the leader in mitochondrial medicine, and the company has assembled a highly experienced management team, board of directors and group of scientific advisors to help it achieve this mission.
[nativounit]
Essentially, primary mitochondrial myopathy, characterized by debilitating skeletal muscle weakness, exercise intolerance and fatigue, which is believed to affect an estimated 40,000 diagnosed individuals in the United States. There are no therapies approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency or the National Medical Products Association of China for the treatment of this indication.
The firm has received Fast Track and Orphan Drug designations from the FDA for the development of elamipretide in this indication. It is conducting a Phase 3 pivotal trial in North America and Europe and expects to have data from that trial by the end of 2019.
Stealth Bio intends to use the net proceeds from this offering to further its pipeline, as well as for working capital and other general corporate purposes, including advancement of its pipeline of discovery compounds.
[recirclink id=515040]
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
